科创板个股中，截至发稿上涨的有506只，下跌的有91只，涨停的有翔宇医疗、伟思医疗、麦澜德等， 跌幅居前的有铂力特、富吉瑞、步科股份等，分别下跌9.17%、7.81%、6.05%。 资金面上，伟思医疗上一交易日主力资金净流入257.84万元，近5日净流入2054.10万元。 1月5日盘中科创板股伟思医疗涨停，截至09:56，股价报58.08元，成交2.79亿元，换手率5.20%，振幅 12.77%。 融资融券数据显示，该股最新（12月31日）两融余额为1.81亿元，其中，融资余额为1.81亿元，较上一 个交易日减少266.96万元，降幅为1.45%；融券余额为9.68万元，较上一个交易日减少20.45万元，降幅 为67.87%。近10日两融余额合计增加635.15万元，增幅为3.63%，其间融资余额增长3.58%，融券余额增 长441.14%。 从机构评级来看，近一个月该股获1家机构买入评级。12月25日西部证券发布的研报给予公司增持评 级。（数据宝） （文章来源：证券时报网） ...

对此，开源证券指出，Neuralink的规模化生产预期+自动化手术方案，以及Merge布局新一代超声波脑 机接口技术具备双重意义。（1）标志着脑机接口从临床验证阶段开始向商业化规模化阶段迈进，推动 脑机接口从"医疗试验工具"到"可普及产品"的落地。2）未来随着技术方案成熟度的进一步提升，也将 为Neuralink脑机接口与特斯拉Optimus人形机器人的协同应用奠定基础。 该机构表示，脑机接口行业正处于技术突破、政策支持、机器人生态协同预期等多重因素驱动下的高增 蓄势期，根据Precedence Research数据，预计到2034年全球脑机接口市场规模将增长到约124亿美元， 2025年—2034年CAGR为17%。在近期Neuralink规模化量产预期和技术突破的催化下，A股脑机接口相 关标的也有望受益。 人脑工程概念5日盘中强势拉升，截至发稿，倍益康30%涨停，三博脑科、翔宇医疗、伟思医疗、美好 医疗等均涨停，熵基科技涨超18%。 消息面上，马斯克近日在社交媒体上表示，旗下Neuralink将在2026年启动脑机接口设备大规模生产，并 同步推进流程高度精简、几乎完全自动化的手术方案，最关键的突破在于，设 ...

消息面上，大摩预期，今年中国人形机器人可出货1.4万台，未来数年将逐年翻倍增长，2034年突破百 万台。 另据每经报道，当地时间2025年12月31日，埃隆.马斯克在社交媒体上表示，其脑机接口公司Neuralink 将于2026年开始对脑机接口设备进行"大规模生产"，还将在脑机植入方式上实现创新。 1月5日电，机器人概念反复活跃，倍益康、翔宇医疗、伟思医疗、熵基科技等涨20%，五洲新春走出4 连板，斯菱智驱涨超15%，双双续创历史新高，汉威科技、蓝思科技、雷迪克、博杰股份等冲高。 | 序号 | 代码 | 名称 | 0 | 最新 | 涨幅% J | | --- | --- | --- | --- | --- | --- | | 1 | 920199 | 倍益康 | 事 | 44.96 | 29.98 | | 2 | 688626 | 翔宇医疗 | 1 | 72.60 | 20.00 | | 3 | 688580 | 伟思医疗 | | 58.08 | 20.00 | | 4 | 301330 | 嫡基科技 | 1 | 39.66 | 20.00 | | 5 | 300753 | 爱朋医疗 | 1 | 33.30 ...

每经AI快讯，1月5日，沪指高开0.46%，深成指高开0.80%，创业板指高开0.84%，人脑工程、贵金属、 石油石化等板块指数涨幅居前。脑机接口概念表现活跃，创新医疗涨停，美好医疗、三博脑科20cm涨 停，倍益康、爱朋医疗、翔宇医疗涨超10%，博拓生物、伟思医疗跟涨。 （文章来源：每日经济新闻） ...

Group 1 - The core viewpoint of the article highlights that Weisi Medical has developed a comprehensive product matrix of rehabilitation robots that covers both upper and lower limbs, integrating various therapeutic technologies [2] - The company aims to provide high-quality solutions for rehabilitation needs, specifically targeting neurological, motor, critical care, and chronic diseases in the elderly [2] - Weisi Medical's approach focuses on meeting the precise demands of improvement-oriented rehabilitation through advanced technology [2]

Market Overview - The medical device sector experienced a decline of 0.74% on December 29, with Huakang Clean leading the drop [1] - The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1] Top Performers - Meihao Medical (301363) saw a closing price of 25.04, with an increase of 8.30% and a trading volume of 197,100 shares, totaling a transaction value of 482 million yuan [1] - Mailande (688273) closed at 41.73, up 8.22%, with a trading volume of 55,200 shares and a transaction value of 227 million yuan [1] - Kangzhong Medical (688607) closed at 45.80, up 7.23%, with a trading volume of 40,200 shares and a transaction value of 180 million yuan [1] Underperformers - Huakang Clean (301235) closed at 39.21, down 8.54%, with a trading volume of 123,300 shares and a transaction value of 488 million yuan [2] - C Jianxin (688805) closed at 47.16, down 7.26%, with a trading volume of 89,000 shares and a transaction value of 426 million yuan [2] - Furuim Medical (300049) closed at 71.93, down 4.20%, with a trading volume of 66,800 shares and a transaction value of 485 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 565 million yuan from institutional investors, while retail investors experienced a net inflow of 328 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Meihao Medical (301363) had a net outflow of 54.30 million yuan from institutional investors, with retail investors also showing a net outflow of 0.76 million yuan [3] - Jigaofazhan (600807) experienced a net inflow of 44.75 million yuan from institutional investors, while retail investors had a net outflow of 61.29 million yuan [3] - Kangzhong Medical (688626) saw a net inflow of 44.26 million yuan from institutional investors, with retail investors showing a slight net outflow [3]

截至2025年12月26日收盘，伟思医疗（688580）报收于48.07元，较上周的46.61元上涨3.13%。本周， 伟思医疗12月25日盘中最高价报50.2元。12月24日盘中最低价报45.79元。伟思医疗当前最新总市值 46.04亿元，在医疗器械板块市值排名77/127，在两市A股市值排名3559/5178。 南京伟思医疗科技股份有限公司拟以11,900万元的价格，将其持有的位于南京市雨花台区宁双路19号9 幢的房屋及配套固定资产转让给江苏云智汇创业投资有限公司。标的资产账面净值为7,994.86万元（截 至2025年9月30日），产权清晰，无抵押或限制转让情形。本次交易不构成关联交易或重大资产重组， 已获董事会审议通过，无需提交股东大会审议。交易预计对公司2026年度归母净利润影响约1,000万 元，对2025年无影响。款项分四期支付，需完成产权过户及资产交割。交易尚存履约不确定性，敬请投 资者注意风险。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公司公告汇总：伟思医疗拟以1.19亿元出售南京雨花台区办公总部资产。 公 ...

Investment Rating - The report maintains an "Overweight" rating for the biomedical sector [4] Core Insights - The brain-computer interface (BCI) industry is at a critical stage of policy support, rapid technological iteration, and accelerated commercialization, with a global market approaching $10 billion [3][9] - The industry is driven by both policy and technology, with significant investments from major countries, including approximately $4.5 billion from the U.S. BRAIN Initiative and hundreds of billions in China [1][51] - The medical application of BCI technology is the most mature segment, focusing on neurorehabilitation, functional replacement, and disease treatment, with a dual growth curve emerging from medical and consumer applications [2][45] Summary by Sections Industry Overview - BCI is defined as a technology that creates a communication channel between the brain and external devices, enabling direct information exchange [16] - BCI can be categorized into invasive, semi-invasive, and non-invasive types, each with distinct applications in medical rehabilitation, consumer interaction, and military use [17][19] - The global BCI market is projected to grow from $1.2 billion in 2019 to approximately $7.63 billion by 2029, with a compound annual growth rate (CAGR) exceeding 13% [24] Policy Guidance - Major countries have launched BCI-related initiatives, with the U.S. and EU leading in funding and research efforts [52][53] - China's "Brain Plan" aims to enhance brain science and BCI technology, with significant funding expected in the coming years [54][57] Clinical Applications - The medical sector is the primary focus for BCI applications, with significant demand driven by conditions such as stroke and disabilities [45][48] - Clinical trials for BCI products are accelerating globally, with notable advancements in both invasive and non-invasive technologies [3][19] Industry Progress - The report highlights the competitive landscape, noting that while foreign companies like Neuralink and Synchron have a head start, domestic firms are making significant strides in key areas such as flexible electrodes and real-time language decoding [2][4][30] - The BCI industry is characterized by a complex supply chain, with upstream components like electrodes and chips, midstream product supply, and downstream applications across various sectors [30][33] Investment Recommendations - Investors are advised to focus on companies with strong technological barriers and clinical application capabilities, particularly in the medical sector, which is the most developed area for BCI commercialization [3][9] - Specific companies to watch include medical scene integrators and leaders in invasive/semi-invasive technologies, such as Xiangyu Medical, Weisi Medical, and Brain Tiger Technology [3][9]

Group 1: Company Overview - The report covers Damai Entertainment (1060.HK), a leading platform in live entertainment, driven by ticketing and IP derivatives [1][6][8] - The company is positioned in a high-growth sector, benefiting from the recovery and structural upgrade of offline entertainment consumption [1][8] - Expected adjusted net profits for FY26-28 are projected at 1.06 billion, 1.35 billion, and 1.58 billion CNY respectively [1][8] Group 2: Industry Insights - The live performance market is experiencing a significant increase, with ticket sales for large concerts expected to exceed 26 billion CNY in 2024, a year-on-year growth of 78.1% [6] - The demand for live entertainment is driven by both personal enjoyment and social needs, with an increase in repeat attendance [6] - The supply side is expanding with diversification in lower-tier cities and various performance categories [6] Group 3: IP Business - Alibaba's IP licensing platform, Aliyu, is a leading player in the market, with a projected GMV of 4.1 billion USD in 2024 [7] - The company is enhancing its collaboration with top IPs, which is expected to contribute significantly to revenue growth [7] - The film industry is still in a recovery phase, with a total box office of 29.23 billion CNY in the first half of 2025, reflecting a year-on-year increase of 22.91% [7] Group 4: Company Financials - Sinopec Engineering (02386.HK) is highlighted as a leading energy and chemical engineering firm with strong technical capabilities and a solid financial performance [10][12] - The company has a high dividend payout ratio, with a dividend yield exceeding 5%, providing stable returns for investors [10][12] - Expected target price for 2026 is set at 9.50 HKD per share, based on a 13x PE ratio [10] Group 5: Market Trends - The petrochemical industry is facing revenue stability but profit pressures, with a slight revenue decline of 2.6% year-on-year in H1 2025 [11] - The trend of "reducing oil and increasing chemicals" is evident, with a 9.94% year-on-year increase in ethylene consumption [11] - Global refining capacity continues to grow, particularly in the Middle East and Asia-Pacific regions, with a projected capital expenditure of 153.35 billion USD in 2024 [11] Group 6: Aviation Sector - Bank of China Aviation Leasing (02588.HK) is positioned to benefit from the rising aviation industry and the ongoing interest rate cut cycle [14][15] - The company ranks fifth globally with a fleet of 483 aircraft, poised to gain from increased revenues as the aviation market recovers [14][15] - Expected total revenue for 2025-2027 is projected at 2.63 billion, 2.85 billion, and 2.94 billion USD, with net profits of 761 million, 894 million, and 964 million USD respectively [16] Group 7: Medical Sector - Weisi Medical (688580.SH) is experiencing steady growth, with projected net profits of 133 million, 165 million, and 184 million CNY for 2025-2027 [4][18] - The company focuses on rehabilitation as its core business while expanding into aesthetic and urology sectors [18][19] - The company emphasizes product innovation in non-invasive brain-machine interfaces, aiming to create a comprehensive neuro-rehabilitation system [19]

Group 1 - The core viewpoint of the news is that Weisi Medical's stock has experienced fluctuations, with a year-to-date increase of 78.09% and a recent decline of 2.03% on December 26 [1] - As of December 26, Weisi Medical's stock price is 48.28 yuan per share, with a market capitalization of 4.624 billion yuan [1] - The company has seen a net outflow of 5.3064 million yuan in principal funds, with significant trading activity reflected in the buying and selling of large orders [1] Group 2 - Weisi Medical, established on January 10, 2001, specializes in the research, production, and sales of rehabilitation medical devices, focusing on areas such as pelvic floor and postpartum rehabilitation, neurological rehabilitation, and mental rehabilitation [2] - The company's revenue composition includes magnetic stimulation (39.44%), consumables and accessories (19.42%), electrophysiology (19.18%), laser radiofrequency (10.26%), electrical stimulation (8.42%), and others (3.28%) [2] - For the period from January to September 2025, Weisi Medical achieved a revenue of 326 million yuan, representing a year-on-year growth of 11.58%, and a net profit attributable to shareholders of 102 million yuan, with a year-on-year increase of 30.68% [2]